A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)

Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1

(2010) Robert M Paris et al.   Expert Review of Vaccines

Prime-boost vectored malaria vaccines: Progress and prospects

(2010) Adrian V. S. Hill et al.   Human vaccines & immunotherapeutics

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

(2010) et al.   NATURE MEDICINE

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

(2010) Scott A. Brown et al.   Viruses-Basel

The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise

(2010) Yegor Voronin et al.   Current Opinion in HIV and AIDS

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

(2010) Glenda Gray et al.   Current Opinion in HIV and AIDS

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)

(2009) Robert J. Amato et al.   JOURNAL OF IMMUNOTHERAPY

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

(2009) Howard L Kaufman et al.   Journal of Translational Medicine

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies

(2009) David A. Garber et al.   PLoS One

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

(2009) Lindvi Gudmundsdotter et al.   VACCINE

A Multigene HIV Type 1 Subtype C Modified Vaccinia Ankara (MVA) Vaccine Efficiently Boosts Immune Responses to a DNA Vaccine in Mice

(2008) Enid Shephard et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Construction, Characterization, and Immunogenicity of a Multigene Modified Vaccinia Ankara (MVA) Vaccine Based on HIV Type 1 Subtype C

(2008) Wendy A. Burgers et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors

(2008) M. Lichterfeld et al.   BLOOD

A heterologous prime/boost immunisation strategy protects against virulent E. ruminantium Welgevonden needle challenge but not against tick challenge

(2008) A. Pretorius et al.   VACCINE